---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003397"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2026-05-14T11:01:18+00:00"
generated_at: "2026-05-14T11:08:30.945297+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; durable remissions without rebound

## Summary
- 72-patient Phase 1 trial met safety and efficacy endpoints; no severe adverse events.
- Cohort 4 (200 mg BID for 56 days): 75% achieved EASI 75, 25% achieved EASI 90, 33% IGA 0/1.
- Biomarker data confirms ITK inhibition reduces Th2/Th17 cytokines and increases persistent Tregs.
- Drug-free remission maintained in post-treatment follow-up (up to 90 days) with no disease rebound.
- SIERRA1 Phase 2 trial for moderate-to-severe atopic dermatitis now enrolling ~200 patients.

## SEC filing metadata
- accession: 0001171843-26-003397
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2026-05-14T11:01:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184326003397/0001171843-26-003397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184326003397/f8k_051426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003397
- JSON: https://secwatch.observer/filing/0001171843-26-003397.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.